MoonLake Immunotherapeutics
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
MLTX$12.56-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| (in thousands, except share and per share data) | September 30, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $379,704 | $334,517 |
| Short-term marketable debt securities | 118,758 | 59,451 |
| Prepaid expenses | 25,933 | 22,857 |
| Other current assets | 8,948 | 4,869 |
| Total current assets | 533,343 | 421,694 |
| Non-current assets | ||
| Operating lease right-of-use assets | 1,713 | 1,566 |
| Property and equipment, net | 443 | 577 |
| Other non-current assets | 5,216 | 596 |
| Total non-current assets | 7,372 | 2,739 |
| Total assets | $540,715 | $424,433 |
| Liabilities and Equity | ||
| Current liabilities | ||
| Trade and other payables | $13,850 | $29,553 |
| Accrued expenses and other current liabilities | 43,621 | 14,691 |
| Short-term portion of operating lease liabilities | 959 | 1,234 |
| Total current liabilities | 58,430 | 45,478 |
| Non-current liabilities | ||
| Long-term debt | 100,010 | 74,100 |
| Long-term portion of operating lease liabilities | 647 | 374 |
| Total non-current liabilities | 100,657 | 74,474 |
| Total liabilities | 159,087 | 119,952 |
| Commitments and contingencies (Note 15) | ||
| Shareholders' equity | ||
| Class A Ordinary Shares: $0.0001 par value per share; 500,000,000 shares authorized; 85,106,685 shares issued and outstanding as of September 30, 2026; 71,373,579 shares issued and outstanding as of December 31, 2025 | 8 | 7 |
| Additional paid-in capital | 1,053,301 | 766,781 |
| Accumulated deficit | (673,968) | (462,911) |
| Accumulated other comprehensive income | 2,287 | 604 |
| Total shareholders’ equity | 381,628 | 304,481 |
| Total liabilities and shareholders' equity | $540,715 | $424,433 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.